Goodwin Procter
Firm overview:
An early specialist in trade secrets practice, Goodwin is highly regarded by industry counterparts for its expertise in this area of IP law. The firm is known for its focus on technology, and has a trade secrets team made up of IP, employment law, privacy and cybersecurity, and business litigation experts.
Goodwin’s team handles trade secrets litigation for innovative companies, entrepreneurs, startup founders and investors. The firm also undertakes deal diligence, identifies risks and proposes solutions to resolve trade secrets concerns that may arise during transactions.
Drawing on its significant expertise, the team provides strategic counselling to clients, including preparing policies and drafting restrictive covenant agreements regarding noncompetition, nondisclosure, and nonsolicitation provisions in employee agreements.
Team overview:
Key contacts in Goodwin’s Trade Secrets, Employee Mobility & Non-Competes group include Koray Bulut (San Francisco), Al Solecki (New York), Andrew Ong (Silicon Valley) and Mark Tully (Boston). Bulut also chairs the firm’s Employment practice and has a litigation-focused practice.
Team members with trade secrets expertise include Stefan Mentzer, who joined Goodwin in 2023 as part of a three-partner move from White & Case. Based in New York, Mentzer’s trade secrets litigation experience includes representing US steel manufacturer Valbruna in a Section 337 proceeding, and acting for Pfizer in trade secrets litigation with Merck.
A big name in the trade secrets arena, Neel Chatterjee left the firm to join King & Spalding in July 2025. Chatterjee has led matters for Silicon Valley’s most well-known technology companies, and previously served on the executive committee at Goodwin.
Key matters:
- Insulet v EOFlow et al
Goodwin represents medical device company Insulet in its widely reported-on dispute over wearable insulin patch pumps with rival company EOFlow.
In a December 2024 judgment, EOFlow was found to have “wilfully and maliciously” stolen four of Insulet’s trade secrets related to its wearable insulin patch pump, the Omnipod, and a Massachusetts jury awarded Insulet a staggering $452 million.
However, that award was drastically reduced by a US federal judge to $59.4 million in April 2025, with the judge citing EOFlow’s inability to pay the original damages amount, among other reasons.
Goodwin’s team was led by partners Robert Carroll (Boston), Robert Frederickson (Boston) and Alexandra Valenti (New York).
The case is Insulet Corporation v EOFlow Co Ltd et al, US District Court for the District of Massachusetts, 23-11780-FDS.
In January 2026, the US Court of Appeals for the Federal Circuit heard oral arguments in EOFlow’s appeal against the injunction. The company also took issue with the damages award, arguing it improperly duplicated the relief already provided by the permanent injunction.
Goodwin’s William Jay argued for Insulet.
- SecurityScorecard v Safe Securities
Goodwin represented Safe Securities, which was sued by SecurityScorecard for allegedly misappropriating trade secrets and confidential and proprietary information.
In October 2025, the parties announced they had resolved their legal dispute and had entered into a collaborative research partnership.
Clients:
Insulet, Safe Securities
